Melatonin induces cell cycle arrest and apoptosis in hepatocarcinoma HepG2 cell line
Javier Martín-Renedo
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD) and Institute of Biomedicine, University of León, León, Spain
Search for more papers by this authorJosé L. Mauriz
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD) and Institute of Biomedicine, University of León, León, Spain
Search for more papers by this authorFrancisco Jorquera
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD) and Institute of Biomedicine, University of León, León, Spain
Search for more papers by this authorOlga Ruiz-Andrés
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD) and Institute of Biomedicine, University of León, León, Spain
Search for more papers by this authorPaquita González
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD) and Institute of Biomedicine, University of León, León, Spain
Search for more papers by this authorJavier González-Gallego
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD) and Institute of Biomedicine, University of León, León, Spain
Search for more papers by this authorJavier Martín-Renedo
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD) and Institute of Biomedicine, University of León, León, Spain
Search for more papers by this authorJosé L. Mauriz
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD) and Institute of Biomedicine, University of León, León, Spain
Search for more papers by this authorFrancisco Jorquera
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD) and Institute of Biomedicine, University of León, León, Spain
Search for more papers by this authorOlga Ruiz-Andrés
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD) and Institute of Biomedicine, University of León, León, Spain
Search for more papers by this authorPaquita González
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD) and Institute of Biomedicine, University of León, León, Spain
Search for more papers by this authorJavier González-Gallego
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD) and Institute of Biomedicine, University of León, León, Spain
Search for more papers by this authorE-mail: [email protected]
Abstract
Abstract: Melatonin reduces proliferation in many different cancer cell lines. However, studies on the oncostatic effects of melatonin in the treatment of hepatocarcinoma are limited. In this study, we examined the effect of melatonin administration on HepG2 human hepatocarcinoma cells, analyzing cell cycle arrest, apoptosis and mitogen-activated protein kinase (MAPK) signalling pathways. Melatonin was dissolved in the cell culture media in 0.2% dimethyl sulfoxide and administered at different concentrations for 2, 4, 6, 8 and 10 days. Melatonin at concentrations 1000–10,000 μm caused a dose- and time-dependent reduction in cell number. Furthermore, melatonin treatment induced apoptosis with increased caspase-3 activity and poly(ADP-ribose) polymerase proteolysis. Proapoptotic effects of melatonin were related to cytosolic cytochrome c release, upregulation of Bax and induction of caspase-9 activity. Melatonin treatment also resulted in increased caspase-8 activity, although no significant change was observed in Fas-L expression. In addition, JNK 1,-2 and -3 and p38, members of the MAPK family, were upregulated by melatonin treatment. Growth inhibition by melatonin altered the percentage or cells in G0–G1 and G2/M phases indicating cell cycle arrest in the G2/M phase. The reduced cell proliferation and alterations of cell cycle were coincident with a significant increase in the expression of p53 and p21 proteins. These novel findings show that melatonin, by inducing cell death and cell cycle arrest, might be useful as adjuvant in hepatocarcinoma therapy.
References
- 1 Okuda K. Hepatocellular carcinoma. J Hepatol 2000; 32: 225–237.
- 2 Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153–156.
- 3 Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979–1994. Lancet 1997; 350: 1142–1143.
- 4 Deuffic S, Poynard T, Buffat L, Valleron AJ. Trends in primary liver cancer. Lancet 1998; 351: 214–215.
- 5 El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745–750.
- 6 El-Serag HB, Davila JA, Petersern NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003; 139: 817–823.
- 7 Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene 2006; 25: 3866–3884.
- 8 Ziedan NI, Kadri H, Westwekll AD. The development of pro-apoptotic cancer therapeutics. Mini Rev Med Chem 2008; 8: 711–718.
- 9 San Miguel B, Alvarez M, Culebras JM, González-Gallego J, Tuñón MJ. N-acetyl-cysteine protects liver from apoptotic death in an animal model of fulminant hepatic failure. Apoptosis 2006; 11: 1945–1957.
- 10 Delhalle S, Duvoix A, Schnekenburger M et al. An introduction to the molecular mechanisms of apoptosis. Ann NY Acad Sci 2003; 1010: 1–8.
- 11 Kim BJ, Ryu SW, Song BJ. JNK- and p38 kinase-mediated phosphorylation of Bax leads to its activation and mitochondrial translocation and to apoptosis of human hepatoma HepG2 cells. J Biol Chem 2006; 281: 21256–21265.
- 12 Lee HJ, Wang CJ, Kuo HC, Chou FP, Jean LF, Tseng TH. Induction apoptosis of luteolin in human hepatoma HepG2 cells involving mitochondria translocation of Bax/Bak and activation of JNK. Toxicol Appl Pharmacol 2005; 203: 124–131.
- 13 Guicciardi ME, Gores GJ. Apoptosis: a mechanisms of acute and chronic liver injury. Gut 2005; 54: 1024–1033.
- 14 Sun Y, Lin R, Dai J, Wang SQ. Suppression of tumour growth using antisense oligonucleotide against survivin in an orthotopic transplant model of human hepatocellular carcinoma in nude mice. Oligonucleotides 2006; 16: 365–374.
- 15 Tengattini S, Reiter RJ, Tan DX, Terron MP, Rodella LF, Rezzani R. Cardiovascular diseases: protective effects of melatonin. J Pineal Res 2008; 44: 16–25.
- 16 Maldonado MD, Murillo-Cabezas F, Terrón MP et al. The potential of melatonin in reducing morbidity–mortality after craniocerebral trauma. J Pineal Res 2007; 42: 1–11.
- 17 Mauriz JL, Molpeceres V, García-Mediavilla MV, González P, Barrio JP, González-Gallego J. Melatonin prevents oxidative stress and changes in antioxidant enzyme expression and activity in the liver of aging rats. J Pineal Res 2007; 42: 222–230.
- 18 Molpeceres V, Mauriz JL, García-Mediavilla MV, González P, Barrio JP, González-Gallego J. Melatonin is able to reduce the apoptotic liver changes induced by aging via inhibition of the intrinsic pathway of apoptosis. J Gerontol A Biol Sci Med Sci 2007; 62: 687–695.
- 19 Jou MJ, Peng TI, Yu PZ et al. Melatonin protects against common deletion of mitochondrial DNA-augmented mitochondrial oxidative stress and apoptosis. J Pineal Res 2007; 43: 389–403.
- 20 Rubio S, Estévez F, Cabrera J et al. Inhibition of proliferation and induction of apoptosis by melatonin in human myeloid HL-60 cells. J Pineal Res 2007; 42: 131.
- 21 Sainz RM, Mayo JC, Rodríguez C, Tan DX, Lopez-Burillo S, Reiter RJ. Melatonin and cell death: differential actions on apoptosis in normal and cancer cells. Cell Mol Life Sci 2003; 60: 1407–1426.
- 22 Hill SM, Blask DE. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cell (MCF-7) in culture. Cancer Res 1988; 48: 6121–6126.
- 23 Papazisis KT, Kouretas D, Geromichalos GD et al. Effects of melatonin on proliferation of cancer cell lines. J Pineal Res 1998; 25: 211–218.
- 24 Petranka J, Baldwin W, Biermann J, Jayadev S, Barrett JC, Murphy E. The oncostatic action of melatonin in an ovarian carcinoma cell line. J Pineal Res 1999; 26: 129–136.
- 25 Farriol M, Venereo Y, Orta X, Castellanos JM, Segovia-Silvestre T. In vitro effects of melatonin on cell proliferation in a colon adenocarcinoma line. J Appl Toxicol 2000; 20: 21–24.
10.1002/(SICI)1099-1263(200001/02)20:1<21::AID-JAT623>3.0.CO;2-M CASPubMedWeb of Science®Google Scholar
- 26 Anisimov VN, Popovich IG, Zabezhinski MA, Anisimov SV, Vesnushkin GM, Vinogradova IA. Melatonin: antioxidant, genoprotector and anticarcinogen. Biochim Biophys Acta 2006; 1757: 573–589.
- 27 García-Navarro A, González-Puga C, Escames G et al. Cellular mechanisms involved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture. J Pineal Res 2007; 43: 195–205.
- 28 Pozo D, Delgado M, Fernandez-Santos JM et al. Expression of the Mel1a-melatonin receptor mRNA in T and B subsets of lymphocytes from rat thymus and spleen. FASEB J 1997; 11: 466–473.
- 29 Blask DE, Sauer LA, Dauchy RT, Holowachuk EW, Ruhoff MS, Kopff HS. Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal transduction events. Cancer Res 1999; 59: 4693–4701.
- 30 Blask DE, Hill SM, Orstead KM, Massa JS. Inhibitory effects of the pineal hormone melatonin and underfeeding during the promotional phase of 7,12-dimethylbenzanthracene (DMBA)-induced mammary tumorigenesis. J Neural Transm 1986; 67: 125–128.
- 31 Qin L, Wang X, Duan Q, Chen B, He S. Inhibitory effect of melatonin on the growth of H22 hepatocarcinoma cells by inducing apoptosis. J Huazhong Univ Sci Technol Med Sci 2004; 24: 19–21.
- 32 Hermann R, Podhajsky S, Jungnickel S, Lerchl A. Potentiation of antiproliferative effects of tamoxifen and ethanol on mouse hepatoma cells by melatonin: possible involvement of mitogen-activated protein kinase and induction of apoptosis. J Pineal Res 2002; 33: 8–13.
- 33 Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. J Inmunol Methods 1986; 89: 271–277.
- 34 Hernández C, Abreu J, Abreu P, Castro A, Jiménez A. Nocturnal melatonin plasma levels in patients with OSAS: the effect of CPAP. Eur Respir J 2007; 30: 496–500.
- 35 Chen ID, Leal BZ, Reiter RJ et al. Melatonin’s inhibitory effect on growth of ME-180 human cervical cancer cells is not related to intracellular glutathione levels. Cancer Lett 1995; 91: 153–159.
- 36 Shiu Syw, Li L, Xu JN, Pang CS, Wong JT, Pang SF. Melatonin-induced inhibition of proliferation and G1/S cell cycle, transition delay of human choriocarcinoma Jar cells: possible involvement of MT2 (MEL1B) receptor. J Pineal Res 1999; 27: 183–192.
- 37 Bennett MR. Apoptosis in the cardiovascular system. Heart (British Cardiac Society) 2002; 87: 480–487.
- 38 García-Santos G, Antolín I, Herrera F et al. Melatonin induces apoptosis in human neuroblastoma cancer cells. J Pineal Res 2006; 41: 130–135.
- 39 Cos S, Fernández F, Sánchez-Barceló EJ. Melatonin inhibits DNA synthesis in MCF-7 human breast cancer cells in vitro. Life Sci 1996; 58: 2447–2453.
- 40 Marelli MM, Limonta P, Maggi R, Motta M, Moretti RM. Growth-inhibitory activity of melatonin on human androgen-independent DU 145 prostate cancer cells. Prostate 2000; 45: 238–244.
- 41 Shiu SY. Towards rational and evidence-based use of melatonin in prostate cancer prevention and treatment. J Pineal Res 2007; 43: 1–9.
- 42 Guha M, Maity P, Choubey V, Mitra K, Reiter RJ, Bandyopadhyay U. Melatonin inhibits free radical-mediated mitochondrial-dependent hepatocyte apoptosis and liver damage induced during malarial infection. J Pineal Res 2007; 43: 372–381.
- 43 Kim SH, Lee SM. Cytoprotective effects of melatonin against necrosis and apoptosis induced by ischemia/reperfusion injury in rat liver. J Pineal Res 2008; 44: 165–171.
- 44 Lakhani SA, Masud A, Kuida K et al. Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science 2006; 311: 847–851.
- 45 Gong Y, Deng S, Zhang M, Wang G, Minuk GY, Burczynski F. A cyclin-dependent kinase inhibitor (p21(WAF1/CIP1)) affects thymidine incorporation in human liver cancer cells. Br J Cancer 2002; 86: 625–629.
- 46 Yang QH, Xu JN, Xu RK, Pang SF. Antiproliferative effects of melatonin on the growth of rat pituitary prolactin-secreting tumor cells in vitro. J Pineal Res 2007; 42: 172–179.
- 47 Trubiani O, Recchioni R, Moroni F, Pizzicannella J, Caputi S, Di Primio R. Melatonin provokes cell death in human B-lymphoma cells by mitochondrial-dependent apoptotic pathway activation. J Pineal Res 2005; 39: 425–431.
- 48 Cowling V, Downward J. Caspase-6 is the direct activator of caspase-8 in the cytochrome c-induced apoptosis pathway: absolute requirement for removal of caspase-6 prodomain. Cell Death Differ 2002; 9: 1046–1056.
- 49 Slee EA, Harte MT, Kluck RM et al. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J Cell Biol 1999; 144: 281–292.
- 50 Herr I, Debatin KM. Cellular stress response and apoptosis in cancer therapy. Blood 2001; 98: 2603–2614.
- 51 Czaja M. The future of GI and liver research: editorial perspectives III. JNK/AP-1 regulation of hepatocyte death. Am J Physiol Gastrointest Liver Physiol 2003; 284: G875–G879.
- 52 Yeh C, Yen G. Induction of apoptosis by the anthocyanidins through regulation of Bcl-2 gene and activation of c-Jun N-terminal kinase cascade in hepatoma cells. J Agric Food Chem 2005; 53: 1740–1749.
- 53 Chan AS, Lai FP, Lo RK, Voyno-Yasenetskaya TA, Stanbridge EJ, Wong YH. Melatonin mt1 and MT2 receptors stimulate c-Jun N-terminal kinase via pertussis toxin-sensitive and -insensitive G proteins. Cell Signal 2002; 14: 249–257.
- 54 Sampath D, Rao VA, Plunkett W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 2003; 22: 9063–9074.
- 55 Boonstra J, Post JA. Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells. Gene 2004; 337: 1–13.
- 56 Atten MJ, Godoy-Romero E, Attar BM, Milson T, Zopel M, Holian O. Resveratrol regulates cellular PKC alpha and delta to inhibit growth and induce apoptosis in gastric cancer cells. Invest New Drugs 2005; 232: 111.
- 57 Filomeni G, Aquilano K, Rotilio G, Ciriolo MR. Reactive oxygen species-dependent c-Jun NH2-terminal kinase/c-Jun signaling cascade mediates neuroblastoma cell death induced by diallyl disulfide. Cancer Res 2003; 63: 5940–5949.
- 58 Vousden KH. p53: death star. Cell 2000; 103: 691–694.
- 59 Schuler M, Green DR. Mechanisms of p53-dependent apoptosis. Biochem Soc Trans 2001; 29: 684–688.
- 60 De Martino A, Filomeni G, Aquilano K, Ciriolo MR, Rotilio G. Effects of water garlic extracts on cell cycle and viability of HepG2 hepatoma cells. J Nutr Biochem 2006; 17: 742–749.
